Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542369 | 0.86 | CYP3A4 (0.65) | CYP3A4HPGDMAPK10MAPK14ALDH1A1 | |
| SCHEMBL2128083 | 0.83 | CYP3A4 (0.48) | CYP3A4HPGDMAPK10MAPK14CRBN | |
| SCHEMBL2745714 | 0.79 | CYP3A4 (0.46) | CYP3A4HPGDMAPK10MAPK14ALDH1A1 | |
| SCHEMBL2128267 | 0.79 | TRPV1 (0.47) | CYP3A4HPGDMAPK10MAPK14ALDH1A1 | |
| SCHEMBL2127702 | 0.79 | CYP3A4 (0.75) | CYP3A4CRBNTRPV1 | |
| SCHEMBL1542479 | 0.79 | CYP3A4 (0.75) | CYP3A4CRBNEPHX2NR1H4TRPV1 | |
| SCHEMBL2127697 | 0.79 | CYP3A4 (0.75) | CYP3A4CRBNTRPV1 | |
| SCHEMBL2129460 | 0.78 | CYP3A4 (0.59) | CYP3A4HPGDMAPK10MAPK14CRBN | |
| SCHEMBL2129383 | 0.77 | CYP3A4 (0.53) | CYP3A4MAPK14ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2130343 | 0.76 | CYP3A4 (0.57) | CYP3A4HPGDMAPK10CRBNCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885HPGD 2497/4885MAPK10 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.